6 citations,
January 2015 in “Evidence-based Complementary and Alternative Medicine” Saw palmetto extract may help treat brain tumors by blocking a specific growth signal and blood vessel formation.
1 citations,
April 2023 in “Science Advances” High levels of ERK activity are key for tissue regeneration in spiny mice, and activating ERK can potentially redirect scar-forming healing towards regenerative healing in mammals.
49 citations,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
July 2022 in “Singapore Medical Journal” Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.
11 citations,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
August 2023 in “Dermatology and Therapy” Experts recommend personalized treatment plans for best outcomes in managing Alopecia Areata.
December 2022 in “Rossijskij žurnal kožnyh i veneričeskih boleznej” New treatments for child hair loss due to immune issues are effective but not yet officially approved.
March 2022 in “Journal of Investigative Dermatology” Discoid Lupus Erythematosus causes scalp plaques that can lead to hair loss, and antimalarial drugs are effective treatments.
2 citations,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
1 citations,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
19 citations,
August 2017 in “American journal of clinical dermatology” Hepatitis B virus exposure may be linked to increased risk of alopecia areata.
38 citations,
June 2015 in “Expert Opinion on Therapeutic Targets” Blocking the prolactin receptor might help treat various diseases, but more research is needed.
2 citations,
November 2019 in “Cancer reports” The Wnt signaling pathway is not a major factor in the development of keratoacanthoma, a type of skin tumor.
9 citations,
July 2017 in “Journal of medical case reports” Ruxolitinib treatment may cause eyelash growth.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.
7 citations,
January 2023 in “Journal of Hematology & Oncology” Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
15 citations,
December 2021 in “Pharmaceutics” The study found key factors in the cause of hidradenitis suppurativa, its link to other diseases, and identified existing drugs that could potentially treat it.
2 citations,
October 2018 in “Archives of Dermatological Research” Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
23 citations,
January 2020 in “Central-European Journal of Immunology/Central European Journal of Immunology” Alopecia areata, a type of hair loss, is likely an autoimmune disease with a genetic link, but its exact cause is still unknown.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
July 2024 in “Clinical Cosmetic and Investigational Dermatology” Exosomes can help promote hair growth and may treat hair loss.
January 2017 in “Journal of Investigative Dermatology Symposium Proceedings” The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.
April 2017 in “Australasian Journal of Dermatology” The session covered updates on skin treatments, including radiotherapy, imiquimod, acitretin, JAK inhibitors, and strategies for managing rosacea and preventing surgical infections.
March 2024 in “Current issues in molecular biology” Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
1 citations,
March 2023 in “Clinical, Cosmetic and Investigational Dermatology” Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
5 citations,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.